阿替利珠单抗(Atezolizumab) - 药物靶点：PDL1_在研适应症：结外NK-T细胞淋巴瘤，晚期非小细胞肺癌，乳腺癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Anti-PDL-1-Genentech/Roche、Atezolizumab (Genetical Recombination)、Atezolizumab (genetical recombination) (JAN)

+ [11]

靶点

PDL1

作用方式

抑制剂

作用机制

PDL1抑制剂(程序性死亡配体1抑制剂)

治疗领域

肿瘤免疫系统疾病消化系统疾病+ [11]

在研适应症

结外NK-T细胞淋巴瘤晚期非小细胞肺癌乳腺癌+ [149]

非在研适应症

大肠腺癌晚期胆管癌晚期胆道癌+ [101]

原研机构

Genentech, Inc.

Universitair Medisch Centrum Groningen

在研机构

Hoffmann-La Roche, Inc.

罗氏（中国）投资有限公司

Roche Diagnostics GmbH

+ [20]

非在研机构

Sanofi

Kymab Ltd.

Pfizer Inc.

+ [13]

权益机构

NeoImmuneTech, Inc.

Harpoon Therapeutics, Inc.Novocure, Inc.

+ [26]

最高研发阶段批准上市

首次获批日期

美国 (2016-05-18),

尿路上皮癌

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、附条件批准 (中国)、孤儿药 (日本)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)、优先审评 (中国)

登录后查看时间轴

结构/序列

Sequence Code 122091L

来源: *****

Sequence Code 4720027H

来源: *****

关联

922

项与阿替利珠单抗相关的临床试验

NCT07388524

/ Recruiting临床3期IIT

Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.

开始日期2027-03-02

申办/合作机构

National Cancer Institute

NCT07170592

/ Not yet recruiting临床1期

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Combination With Hydroxyurea or Hydroxyurea/Atezolizumab in Treatment-refractory Solid Tumor Patients

This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of cancer.

开始日期2027-01-01

申办/合作机构

Bionoxx, Inc.

NCT07322341

/ Not yet recruiting临床2期IIT

A Phase 2 Trial of SX-682 and Atezolizumab in Patients With Advanced NSCLC Who Progressed on Prior Chemotherapy and Immune Checkpoint Inhibitor (ICI) Therapy

This phase II trial tests how well SX-682 and atezolizumab works for the treatment of non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic), and has come back after a period of improvement (recurrent). SX-682 blocks proteins that may be able to stimulate the immune system to kill and eliminate tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SX-682 and atezolizumab may be effective for the treatment of advanced or metastatic, recurrent NSCLC.

开始日期2026-09-01

申办/合作机构

University of Washington

[+3]

100 项与阿替利珠单抗相关的临床结果

登录后查看更多信息

100 项与阿替利珠单抗相关的转化医学

登录后查看更多信息

100 项与阿替利珠单抗相关的专利（医药）

登录后查看更多信息

4,577

项与阿替利珠单抗相关的文献（医药）

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia

Article

作者: Chaiyakunapruk, Nathorn ; Patikorn, Chanthawat ; Sulaiman Shah, Audi Adawiah ; Wong, Yoke Fui ; Mohamed, Rosmawati

AIM:

This study aims to evaluate the cost-effectiveness of atezolizumab plus bevacizumab as first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC) in Malaysia, compared with the current standard treatments in the Malaysian Ministry of Health (MOH) to inform public healthcare decision‑making.

MATERIALS AND METHODS:

A cost-effectiveness analysis was conducted from the MOH perspective, following the national pharmacoeconomic guidelines (2019). The study compared atezolizumab plus bevacizumab with sorafenib and lenvatinib, respectively, using a partitioned survival model to project health outcomes and costs over a lifetime horizon. Clinical efficacy data were sourced from published trials and network meta-analyses. Cost inputs reflected local healthcare resource use and prices, using 2024 Malaysian Ringgit values inflated via the Consumer Price Index for Health. Costs and outcomes were discounted at 3% annually. Deterministic and probabilistic sensitivity analyses were performed to assess the impact of key parameter uncertainties on the results.

RESULTS:

Atezolizumab plus bevacizumab provided the highest quality-adjusted life years (QALYs) and life years compared to sorafenib and lenvatinib. Sorafenib was dominated by lenvatinib due to lower QALYs and higher costs and excluded from further analysis. Compared to lenvatinib, atezolizumab plus bevacizumab yielded 0.873 additional QALYs and RM 44,863 additional cost, resulting in an incremental cost-effectiveness ratio (ICER) of RM 51,399 per QALY gained (∼0.906 GDP/capita at Malaysia's 2024 GDP/capita RM 56,734).

CONCLUSIONS:

Atezolizumab plus bevacizumab is cost-effective compared to lenvatinib and sorafenib across willingness-to-pay (WTP) values of one to three times Malaysia's GDP per capita. These findings provide evidence to inform public health policy that expanding funding and adoption of atezolizumab plus bevacizumab is likely to improve health outcomes cost-effectively.

2026-10-01·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Integrating multiple outcomes of first-line immunotherapy-based regimens for advanced hepatocellular carcinoma: A network meta-analysis of phase III trials

Review

作者: Li, Xinming ; Kong, Qingyan ; Nie, Guilin ; Xu, Jianrong ; Yang, Jiaqi ; Liu, Geng ; Wang, Yaoqun ; Li, Bei ; Lu, Jiong

BACKGROUND:

Immunotherapy-based regimens are standard first-line treatments for advanced hepatocellular carcinoma (HCC), yet integrated comparisons across efficacy, safety, and quality-of-life (QoL) outcomes remain limited. We performed a network meta-analysis (NMA) to identify the optimal treatment strategy.

METHODS:

A literature search was conducted in PubMed, Embase, Cochrane Library, and Scopus to identify phase III randomized controlled trials (RCTs) evaluating immune checkpoint inhibitor (ICI)-based therapies. A Bayesian network meta-analysis was conducted to compare overall survival (OS), progression-free survival (PFS), tumor response, safety and QoL, with treatment rankings estimated using surface under the cumulative ranking curve (SUCRA) values. A subgroup analysis was conducted. A multi-criteria decision making approach, entropy-weighted Technique for Order Preference by Similarity to Ideal Solution (TOPSIS) model was conducted to integrate efficacy, safety, and health-related QoL outcomes RESULTS: Twelve RCTs involving 7908 patients met inclusion criteria. Sintilimab plus IBI305 showed the highest probability of being the most effective treatment for overall survival with highest SUCRA scores (0.91). Finotonlimab plus bevacizumab was most likely to improve overall survival in younger patients (0.95) and those with HBV-related HCC (0.84), as well as PFS in the overall population (0.86). When integrating efficacy, safety, and health-related QoL outcomes, finotonlimab plus bevacizumab and atezolizumab plus bevacizumab demonstrated superior overall performance compared with all other regimens.

CONCLUSIONS:

Bevacizumab-based immunotherapy combinations (finotonlimab plus bevacizumab and atezolizumab plus bevacizumab) provide a favorable benefit-risk balance in advanced HCC. The robust performance of finotonlimab plus bevacizumab highlights its translational potential. Composite points such as Topsis may facilitate integrated multiple outcomes.

2026-09-01·COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY

Toxic effects of acute atrazine exposure on the physiological functions and transcriptional levels in non-targeted marine invertebrates (Chlamys nobilis)

Article

作者: Sun, Jing ; Zheng, Huaiping ; Liu, Yaoting ; Yan, Beiyu ; Lin, Qing ; Wang, Weili ; Zhang, Hongkuan

Atrazine (ATZ), the second most widely used pesticide globally, poses potential risks to non-target aquatic organisms. However, its toxicological impacts on the economically valuable Chlamys nobilis remain unknown. This study investigates the toxicological effects of ATZ on the economically important C. nobilis. We assessed tissue integrity, physiological functions, and transcriptional profiles following ATZ exposure. Mortality in C. nobilis was observed to be time- and dose-dependent. Gill tissue damage was first noted at 5 μg/L ATZ, with severity increasing at higher concentrations. Superoxide dismutase (SOD) and catalase (CAT) activities were significantly elevated at 5 μg/L and 50 μg/L compared to controls but declined at 500 μg/L (P < 0.05). Glutathione S-transferase (GST) activity increased in all exposed groups except at 500 μg/L, peaking at 5 μg/L (P < 0.05). Malondialdehyde (MDA) levels rose significantly at 0.5 μg/L and further increased with higher ATZ concentrations (P < 0.05). RNA-seq analysis revealed 167 and 282 differentially expressed genes (DEGs) at 0.5 μg/L and 50 μg/L, respectively, enriched in pathways related to the endocrine, sensory, and digestive systems. Our findings highlight the toxic effects of ATZ on C. nobilis and contribute to the environmental risk assessment of this pesticide.

3,742

项与阿替利珠单抗相关的新闻（医药）

2026-08-05

·PRNewswire

SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer

REDMOND, Wash., Aug. 5, 2026 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company and subsidiary of Biokin, today announced that the first patient has been dosed in BrenDeLL-Lung01 (NCT07625644), a global Phase 3 registrational trial evaluating BL-M14D1 in combination with atezolizumab for the treatment of patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC). BL-M14D1 is an investigational DLL3-targeted antibody-drug conjugate (ADC) built on SystImmune's proprietary brengitecan platform and is being developed globally for the treatment of small cell lung cancer and other neuroendocrine malignancies. "The initiation of our global Phase 3 program marks an important milestone for BL-M14D1 and reflects our commitment to bringing innovative treatment options to patients with small cell lung cancer," said Jonathan Cheng, M.D., Chief Medical Officer of SystImmune. "Despite recent advances, outcomes for patients with extensive-stage small cell lung cancer remain poor, and there continues to be a significant need for more effective therapies. We believe BL-M14D1 has the potential to improve outcomes for these patients, and we are excited to begin evaluating the program in a registrational setting." The Phase 3 study follows encouraging clinical activity observed in the ongoing Phase 1 BL-M14D1-101 trial recently presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. These results demonstrated promising anti-tumor activity and a manageable safety profile in heavily pre-treated patients with small cell lung cancer and other neuroendocrine carcinomas, supporting advancement of the program into late-stage development. About the BrenDeLL-Lung01 Phase 3 Clinical Trial BrenDeLL-Lung01 (NCT07625644) is a global, multi-center, randomized Phase 3 trial evaluating BL-M14D1 in combination with atezolizumab versus standard-of-care platinum and etoposide induction followed by atezolizumab maintenance, with or without lurbinectedin, in patients with previously untreated extensive-stage small cell lung cancer. The study intends to enroll approximately 580 patients and the primary endpoint for this study is progression-free survival as assessed by blinded independent central review (BICR). About BL-M14D1 SystImmune is advancing a portfolio of next-generation antibody-drug conjugates (ADCs) built on its proprietary brengitecan platform, which utilizes a potent topoisomerase I inhibitor payload designed for targeted delivery to tumor cells. The clinical progress of izalontamab brengitecan (iza-bren) provides initial validation of this platform's potential to deliver meaningful anti-tumor activity across multiple cancer types. BL-M14D1 targets DLL3, which is highly expressed in small-cell lung cancer and neuroendocrine tumors, facilitating selective delivery of the brengitecan payload to DLL3-positive tumor cells. About SystImmune SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has several assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the potential clinical benefits of iza-bren, the timing and outcomes of regulatory interactions, and the future development and commercialization of iza-bren. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. SystImmune undertakes no obligation to update any forward-looking statements contained herein, except as required by law. SOURCE SystImmune, Inc. 21% more press release views with Request a Demo

2026-08-04

·中金在线港股频道

恒瑞医药(01276)：SHR-A2009、阿得贝利单抗注射液获得药物临床试验批准通知书

智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称“公司”)子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局(以下简称　　“国家药监局”)核准签发关于注射用 SHR-A2009、阿得贝利单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。　　注射用 SHR-A2009 是一款以 HER3 为靶点的抗体药物偶联物，可特异性结合肿瘤细胞表面上的　　HER3，进而被内吞至细胞内并转运至溶酶体中，水解释放游离毒素，杀伤肿瘤细胞。目前该项目单药用于非小细胞肺癌临床试验的上市许可申请已受理，全球尚无获批治疗　　NSCLC 的以 HER3 为靶点的 ADC。截至目前，注射用 SHR-A2009 相关项目累计研发投入约 32,950 万元(未经审计)。　　阿得贝利单抗注射液是公司自主研发的人源化抗 PD-L1 单克隆抗体，能通过特异性结合 PD-L1 分子从而阻断导致肿瘤免疫耐受的 PD-1/PD-L1 　　通路，重新激活免疫系统的抗肿瘤活性，从而达到治疗肿瘤的目的。公司阿得贝利单抗注射液已获批两项适应症，分别为：与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗;联合含铂化疗作为新辅助治疗，术后继续以本品作为单药辅助治疗，用于治疗可手术切除的Ⅱ、ⅢA 　　和ⅢB 期且无已知表皮生长因子受体(EGFR)突变或间变性淋巴瘤激酶(ALK)重排的成人非小细胞肺癌(NSCLC)患者。国外有同类产品　　Atezolizumab(商品名： Tecentriq)、 Avelumab(商品名：Bavencio)和　　Durvalumab(商品名：Imfinzi)于美国获批上市销售，其中 Atezolizumab 和 Durvalumab 　　已在中国获批上市。国内另有多款同类产品获批上市。经查询，2025 年 Atezolizumab、Avelumab 和 Durvalumab 全球销售额合计约为　　110.54 亿美元。截至目前，阿得贝利单抗注射液相关项目累计研发投入约 125,190 万元(未经审计)。该信息由智通财经网提供

2026-08-04

·FiercePharma

Jazz to withdraw Zepzelca with FDA in second-line small cell lung cancer

After a yearslong struggle, Jazz Pharmaceuticals has called time on Zepzelca as a second-line treatment for small cell lung cancer. In alignment with the FDA, Jazz plans to ask the agency to remove the second-line SCLC indication from Zepzelca’s label, the company said Monday alongside its second-quarter earnings report. The decision comes after the confirmatory phase 3 Lagoon trial recently failed on its primary endpoint of overall survival. In the study, Zepzelca (lurbinectedin) monotherapy performed even worse than other chemotherapy regimens, while a combination of Zepzelca and irinotecan showed a numerical advantage that didn’t meet statistical significance. The withdrawal does not affect Zepzelca’s first-line maintenance approval as part of a combination with Roche’s Tecentriq for patients with extensive-stage SCLC. Zepzelca’s troubles quickly began to show after its initial FDA go-ahead in second-line SCLC. Just half a year after accelerated approval, the PharmaMar-partnered drug failed in the randomized phase 3 Atlantis trial, which evaluated the chemotherapy in tandem with doxorubicin versus the physician’s choice of chemo in second-line SCLC. Despite the flop, the FDA allowed Zepzelca to remain on the market and, in 2022, rejected a citizen petition calling for its withdrawal. At the time, the agency noted that the Atlantis study used a lower dose of Zepzelca than its approved version, and that an unmet medical need exists in second-line SCLC. Since then, the agency has approved Amgen’s T-cell engager Imdelltra in previously treated SCLC. The Lagoon trial used standard-dose Zepzelca for its single-agent regimen. Commercially, the first-line maintenance nod has given Zepzelca a boost. Sales of the drug in the second quarter increased 42% year over year to $106 million, as Jazz attributed the growth solely to its first-line use. Still, second-line uses make up the majority of Zepzelca’s uptake, with around 30% to 40% of the drug’s U.S. sales coming from the first-line setting, according to Jazz’s chief commercial officer, Sam Pearce, on an investor call Monday. Even before the withdrawal decision, Jazz had already seen a gradual decline in its second-line business due to competition. Now, “we may expect that to accelerate,” Pearce said. Cancer drugmakers have mostly been cooperative in withdrawing their drugs or indications after the FDA ramped up its post-accelerated approval scrutiny in recent years. In 2022, GSK quickly announced plans to remove its antibody-drug conjugate Blenrep merely days after a confirmatory trial flop in third-line multiple myeloma. The British pharma managed to reintroduce the drug as part of a combination last year after new phase 3 wins. Other oncology market withdrawals in recent years as a result of confirmatory trial setbacks include Takeda’s EGFR inhibitor Exkivity in lung cancer, Gilead’s ADC Trodelvy in bladder cancer and Ipsen’s EZH2 inhibitor Tazverik in blood cancer.

临床3期加速审批临床结果抗体药物偶联物

100 项与阿替利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10773	阿替利珠单抗	L01XC32	DB11595

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
结外NK-T细胞淋巴瘤	日本	Chugai Pharmaceutical Co., Ltd.	2025-09-19
晚期非小细胞肺癌	欧盟	Roche Registration GmbH	2024-07-25
晚期非小细胞肺癌	冰岛	Roche Registration GmbH	2024-07-25
晚期非小细胞肺癌	列支敦士登	Roche Registration GmbH	2024-07-25
晚期非小细胞肺癌	挪威	Roche Registration GmbH	2024-07-25
乳腺癌	加拿大	F. Hoffmann-La Roche Ltd.	2024-03-13
肺泡软组织肉瘤	美国	Genentech, Inc.	2022-12-09
PD-L1阳性非小细胞肺癌	日本	Chugai Pharmaceutical Co., Ltd.	2022-05-26
BRAF V600 突变阳性黑色素瘤	美国	Genentech, Inc.	2020-07-30
PD-L1阳性三阴性乳腺癌	日本	Chugai Pharmaceutical Co., Ltd.	2018-01-19
晚期肝细胞癌	欧盟	Roche Registration GmbH	2017-09-20
晚期肝细胞癌	冰岛	Roche Registration GmbH	2017-09-20
晚期肝细胞癌	列支敦士登	Roche Registration GmbH	2017-09-20
晚期肝细胞癌	挪威	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	欧盟	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	冰岛	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	列支敦士登	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	挪威	Roche Registration GmbH	2017-09-20
广泛期小细胞肺癌	欧盟	Roche Registration GmbH	2017-09-20
广泛期小细胞肺癌	冰岛	Roche Registration GmbH	2017-09-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
错配修复缺陷或微高卫星不稳定性结肠癌	申请上市	澳大利亚	Roche Products Pty Ltd.	2026-04-08
肌层浸润性膀胱癌	申请上市	日本	Chugai Pharmaceutical Co., Ltd.	2026-01-28
膀胱癌	申请上市	中国	Roche Holding AG	2019-02-25
淋巴组织增生性疾病	临床3期	英国	Hoffmann-La Roche Ltd.	2023-10-25
黑色素瘤	临床3期	英国	Hoffmann-La Roche Ltd.	2023-10-25
MSI-H 癌症	临床3期	英国	Hoffmann-La Roche Ltd.	2023-10-25
Turcot综合征	临床3期	英国	Hoffmann-La Roche Ltd.	2023-10-25
局部晚期乳腺癌	临床3期	美国	Roche Diagnostics GmbH	2021-03-29
局部晚期乳腺癌	临床3期	美国	罗氏（中国）投资有限公司	2021-03-29
局部晚期乳腺癌	临床3期	美国	F. Hoffmann-La Roche Ltd.	2021-03-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04776447 (APOLLO \| APOLO, CTgov)	临床2期	可切除非小细胞肺癌 \| 非小细胞肺癌IIIA期 \| 支气管癌 ... 更多	38	Carboplatin+Placlitaxel+Atezolizumab	艱襯糧鹽鹽選艱鏇鬱廠 = 窪壓窪艱鏇窪築鏇繭鹽構膚築衊糧築簾簾憲觸 (獵獵鹽壓衊繭廠醖鏇積, 鹽繭願簾顧襯醖壓鏇鑰 ~ 鹹醖廠鑰構選遞築壓顧) 更多	-	2026-07-22
ESMO_GI2026 \| ESMO_GCC2026	N/A	肝细胞癌二线	60	atezolizumab-bevacizumab	艱醖繭積廠選遞簾襯鬱(鹽繭糧積選蓋鹹齋鏇遞) = Adverse events were predominantly low-grade, most commonly fatigue (7, 31.8%) and diarrhea (4, 18.2%). 蓋構艱鏇選襯鬱鹹鹽觸 (鑰網窪繭鹽憲鹹憲鹽鬱 )	积极	2026-07-02
				Lenvatinib (second-line therapy)
ESMO_GI2026 \| ESMO_GCC2026	N/A	肝细胞癌	71	Atezolizumab plus Bevacizumab	獵鏇鑰範襯淵餘膚淵構(製願積醖製築鏇齋壓膚) = 淵鹹鹹廠淵餘壓範獵簾壓糧繭鬱製遞齋憲獵餘 (餘衊網觸網壓範獵製襯 ) 更多	积极	2026-07-02
				Durvalumab plus Tremelimumab	繭艱選簾艱糧憲鬱醖願(淵鑰糧鹹製醖製夢鬱膚) = 積憲襯顧製製簾糧簾鹹醖齋壓壓鏇顧網夢窪鹽 (觸壓蓋醖糧築膚廠夢窪 )
NCT04732286 (ATHECA, ESMO_GI2026 \| ESMO_GCC2026)	临床3期	不可切除的肝细胞癌一线	99	Atezolizumab plus bevacizumab (Atezo+Bev)	醖構鏇鑰築廠繭糧醖網(築鑰淵鹽製艱壓築範積) = 廠壓憲鑰顧衊鹽餘範壓襯獵鹽構鑰願蓋襯廠糧 (夢積獵糧積廠膚餘鬱觸, NE ~ NE) 更多	积极	2026-07-02
				Sorafenib	醖構鏇鑰築廠繭糧醖網(築鑰淵鹽製艱壓築範積) = 淵顧選願觸製選蓋窪遞襯獵鹽構鑰願蓋襯廠糧 (夢積獵糧積廠膚餘鬱觸, 14.64 ~ 29.98) 更多
ESMO_GI2026 \| ESMO_GCC2026	N/A	肝细胞癌一线	46	Atezolizumab-Bevacizumab (AB)	廠膚膚鬱積壓醖淵窪廠(觸鏇願遞齋觸蓋構憲築) = 顧夢範構鬱範積鏇鏇簾顧壓積衊網糧廠觸窪顧 (糧觸襯鹹願鏇醖觸憲鹽 ) 更多	积极	2026-07-02
				Atezolizumab-Bevacizumab (AB) (Without a decline in AFP ≥20% at 12 weeks)	廠膚膚鬱積壓醖淵窪廠(觸鏇願遞齋觸蓋構憲築) = 製壓糧構鹽獵選鏇製廠顧壓積衊網糧廠觸窪顧 (糧觸襯鹹願鏇醖觸憲鹽 ) 更多
ESMO_GI2026 \| ESMO_GCC2026	N/A	不可切除的肝细胞癌一线	69	Modified iTACE combined with atezolizumab plus bevacizumab	鬱願衊衊遞膚鏇糧鏇憲(夢夢繭襯艱鏇顧製餘鑰) = 遞鹹觸憲繭淵壓鑰廠製齋鬱餘鑰積艱壓範選衊 (鹽構窪獵鬱鹹獵壓鹽廠 ) 更多	积极	2026-07-02
NCT05537402 (LOST-B, CTgov)	临床2期	肝细胞癌	1	Atezolizumab+Bevacizumab (Arm A: Atezolizumab and Bevacizumab)	蓋積選製製繭鹽醖餘糧(製鑰醖鏇鏇憲鏇齋窪觸) = 構鑰夢衊壓遞構艱鬱膚選醖構鹹網餘繭餘鏇鏇 (艱衊醖觸窪製願觸鏇淵, 範獵範憲廠糧艱齋廠鹽 ~ 窪齋鹹夢艱鏇鹹夢範獵) 更多	-	2026-06-18
				transarterial chemoembolization (TACE) or transarterial radioembolization (TARE (Arm B: Locoregional Therapy With TACE or TARE)	蓋積選製製繭鹽醖餘糧(製鑰醖鏇鏇憲鏇齋窪觸) = 築壓築淵齋網觸蓋膚選選醖構鹹網餘繭餘鏇鏇 (艱衊醖觸窪製願觸鏇淵, 壓蓋鬱鑰艱糧鏇壓夢選 ~ 艱夢壓獵衊選鹽範鑰選) 更多
NCT04829383 (BTCRC-GI20-457 \| AB7, CTgov)	临床2期	不可切除的肝细胞癌	6	Atezolizumab+Bevacizumab	簾獵鑰觸鹽簾願願願鑰 = 繭鑰繭積選範衊製廠膚鹽簾顧艱鹽築築範積衊 (艱鹽壓齋夢憲觸網艱淵, 鹹襯鑰衊夢壓衊構醖壓 ~ 艱蓋簾築網襯窪齋夢觸) 更多	-	2026-06-16
NCT04984811 (CTgov)	临床2期	非小细胞肺癌 \| 非小细胞肺癌 III期 \| 转移性非小细胞肺癌	33	Atezoliaumab+NT-I7	鏇簾淵衊衊鑰糧鬱餘齋 = 遞築憲構範窪鹹襯糧餘窪鹽簾鏇衊鑰繭淵願製 (簾獵憲鏇廠憲廠廠獵壓, 構願網襯顧齋築夢構選 ~ 衊蓋範鑰獵繭簾觸遞憲) 更多	-	2026-06-11
NCT04619797 (SKYSCRAPER-06, CTgov)	临床2/3期	晚期肺非鳞状非小细胞癌	542	Pembrolizumab+Placebo (Placebo + Pembrolizumab + Chemotherapy)	鏇願鹹鏇夢淵願鏇襯壓(範鑰觸願襯顧衊夢醖網) = 鏇遞鑰網艱壓鬱壓簾蓋顧鹹餘獵鏇蓋艱醖衊夢 (醖淵顧鬱淵遞鏇築範憲, 蓋鏇醖鬱觸觸範膚鑰顧 ~ 衊襯餘淵餘糧廠醖製範) 更多	-	2026-06-03
				Atezolizumab+Tiragolumab (Tiragolumab + Atezolizumab + Chemotherapy)	鏇願鹹鏇夢淵願鏇襯壓(範鑰觸願襯顧衊夢醖網) = 網蓋鏇鏇糧願鹽醖鹽餘顧鹹餘獵鏇蓋艱醖衊夢 (醖淵顧鬱淵遞鏇築範憲, 鏇範夢膚鏇糧觸鏇衊鏇 ~ 範憲淵窪繭糧齋製壓廠) 更多